Digestive Disease & Surgery Institute Outcomes
Pancreaticobiliary Disease
Pancreatectomy
Cleveland Clinic pancreatic surgeons treat a wide array of disease processes. These consist of both benign and malignant diseases of the pancreas, duodenum, bile ducts, and gallbladder. Multiple multidisciplinary teams expand to experts in Radiology, Oncology, Gastroenterology, Pathology, and Psychology, allowing the team to determine the best tailored treatment plan for each individual patient.
Distal Pancreatectomy ACS NSQIP Outcomes
January 1, 2024 – December 31, 2024
The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP®) objectively measures and reports risk-adjusted surgical outcomes based on a defined sampling and abstraction methodology. These outcomes data reflect Cleveland Clinic’s overall distal pancreatectomy ACS NSQIP performance benchmarked against 163 participating sites.
| Distal Pancreatectomy (163 Sites) | N | Observed | Expected |
|---|---|---|---|
| 30 Day Mortality | 49 | 2.04% | 14.74% |
| 30 Day Morbidity | 49 | 2.04% | 2.49% |
| Cardiac | 49 | 2.04% | 1.04% |
| Pneumonia | 49 | 4.08% | 1.91% |
| Unplanned Intubation | 49 | 2.04% | 10.04% |
| Deep Vein Thrombosis (DVT) / Pulmonary Embolus | 49 | 0.00% | 1.45% |
| Surgical Site Infection (SSI) | 49 | 2.04% | 10.04% |
| Sepsis | 49 | 2.04% | 1.28% |
| Unplanned Reoperation | 49 | 4.08% | 2.21% |
| Length of Stay | 46 | 21.74% | 18.68% |
| Unplanned Readmission | 49 | 10.20% | 15.58% |
| Fistula | 49 | 0.00% | 9.25% |
| Delayed Gastric Emptying | 49 | 4.08% | 2.40% |
American College of Surgeons National Surgical Quality Improvement Program, 2025.
ACS NSQIP® Semiannual Report July, 2025, Chicago: American College of Surgeons.
Whipple Pancreatectomy ACS NSQIP Outcomes
January 1, 2024 – December 31, 2024
The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP®) objectively measures and reports risk-adjusted surgical outcomes based on a defined sampling and abstraction methodology. These outcomes data reflect Cleveland Clinic’s overall Whipple Pancreatectomy ACS NSQIP performance benchmarked against 164 participating sites.
Cleveland Clinic has been rated as ‘exemplary’ on three primary Whipple Pancreatectomy outcomes: morbidity, surgical site infection (SSI) and fistula and is rated as the single best in the US based on overall morbidity data.
| Whipple Pancreatectomy (164 Sites) | N | Observed | Expected |
|---|---|---|---|
| 30 Day Mortality | 89 | 0.00% | 0.85% |
| 30 Day Morbidityᵇ | 89 | 10.11% | 23.18% |
| Cardiac | 89 | 0.00% | 1.52% |
| Pneumonia | 89 | 1.12% | 2.29% |
| Unplanned Intubation | 89 | 1.12% | 2.35% |
| Ventilator > 48 Hours | 89 | 2.25% | 1.60% |
| Deep Vein Thrombosis (DVT) / Pulmonary Embolus | 89 | 4.49% | 3.65% |
| Renal Failure | 89 | 2.25% | 3.13% |
| Urinary Tract Infection (UTI) | 89 | 0.00% | 1.54% |
| Surgical Site Infection (SSI)ᵇ | 89 | 6.74% | 16.92% |
| Sepsis | 89 | 0.00% | 4.20% |
| C.diff Colitis | 89 | 1.12% | 0.72% |
| Unplanned Reoperation | 89 | 2.25% | 3.09% |
| Length of Stay | 78 | 15.38% | 19.79% |
| Unplanned Readmission | 89 | 8.99% | 17.66% |
| Fistula | 89 | 6.74% | 11.94% |
| Delayed Gastric Emptying | 89 | 7.87% | 14.90% |
American College of Surgeons National Surgical Quality Improvement Program, 2025.
ACS NSQIP® Semiannual Report July, 2025, Chicago: American College of Surgeons.
ᵃIdentified as a statistical outlier (higher than expected) by the ACS NSQIP hierarchical model.
ᵇIdentified as a statistical outlier (lower than expected) by the ACS NSQIP hierarchical model.
